FDA sets Feb. 26 review of Johnson & Johnson COVID-19 vaccine data

The Food and Drug Administration last night announced that its Vaccines and Related Biological Products Advisory Committee will convene Feb. 26 to discuss the emergency use authorization application by Johnson & Johnson and Janssen Biotech, Inc. for its investigational single-dose COVID-19 vaccine candidate.
The Johnson & Johnson candidate is the third to seek an EUA from the agency; the application follows topline efficacy and safety data culled from a phase 3 trial that showed a 72% effectiveness in the U.S. for preventing moderate-to-severe COVID-19.
Related News Articles
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…